Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 51Small Cell Lung Carcinoma 23Breast Neoplasms 18Sarcoma 17Lung Neoplasms 10Carcinoma, Hepatocellular 10Esophageal Squamous Cell Carcinoma 9Stomach Neoplasms 8Neoplasms 8Triple Negative Breast Neoplasms 7Ovarian Neoplasms 7Nasopharyngeal Carcinoma 7Thyroid Neoplasms 6Neoplasm Metastasis 6Esophageal Neoplasms 6Pancreatic Neoplasms 5NSCLC 5Colorectal Neoplasms 5Carcinoma 5Uterine Cervical Neoplasms 4Pheochromocytoma 4Endometrial Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Ovarian Epithelial 4Recurrence 3Paraganglioma 3Non-squamous Non-small Cell Lung Cancer 3Glioma 3Fallopian Tube Neoplasms 3Cholangiocarcinoma 3

Interventions

vandetanib 1trametinib 1pralsetinib 1lenvatinib 1larotrectinib 1entrectinib 1donafenib 1dabrafenib 1cabozantinib 1apatinib 1anlotinib 1Sorafenib 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Locally Advanced Thyroid Gland Carcinoma × anlotinib × Clear all
NCT06482086 2024-12-05

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

West China Hospital

Phase 2 Recruiting
75 enrolled
Head & Neck

Locally Advanced Thyroid Gland Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡